CTI Biopharma traded at $5.82 this Friday September 23rd, increasing $0.03 or 0.52 percent since the previous trading session. Looking back, over the last four weeks, CTI Biopharma gained 11.95 percent. Over the last 12 months, its price rose by 91.45 percent. Looking ahead, we forecast CTI Biopharma to be priced at 5.65 by the end of this quarter and at 5.16 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Applied Genetic Technologies 0.29 -0.01 -2.01% -90.96%
Baxter International 55.41 0.04 0.07% -31.47%
Bristol-Myers Squibb 70.71 -0.58 -0.81% 17.40%
CTI Biopharma 5.82 0.03 0.52% 91.45%
Plus Therapeutics, Inc. 0.50 0.01 2.04% -74.87%
Geron 2.30 -0.16 -6.50% 67.88%
Incyte Corp 66.89 -0.52 -0.77% -3.06%
Eli Lilly 311.46 0.59 0.19% 34.44%
Mirati Therapeutics 68.18 -1.76 -2.52% -59.02%
Novartis 73.95 -0.41 -0.55% -3.91%
Novartis 76.01 -1.13 -1.46% -8.34%
Northwest Biotherapeutics 0.71 -0.03 -3.42% -51.71%
Seattle Genetics 139.20 -1.35 -0.96% -13.72%
Teva Pharmaceutical Industries 7.90 -0.16 -1.99% -11.73%

Indexes Price Day Year
USND 10868 -198.88 -1.80% -27.78%
US2000 1680 -42.72 -2.48% -25.29%

CTI Biopharma
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.